176 related articles for article (PubMed ID: 17048354)
1. Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome.
Dixon N; Kishnani PS; Zimmerman S
Am J Med Genet C Semin Med Genet; 2006 Aug; 142C(3):149-57. PubMed ID: 17048354
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
3. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome.
Zipursky A; Brown EJ; Christensen H; Doyle J
Clin Lab Med; 1999 Mar; 19(1):157-67, vii. PubMed ID: 10403079
[TBL] [Abstract][Full Text] [Related]
4. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Xavier AC; Ge Y; Taub JW
J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
[TBL] [Abstract][Full Text] [Related]
5. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
[TBL] [Abstract][Full Text] [Related]
6. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
7. Hematological disorders and leukemia in children with Down syndrome.
Bruwier A; Chantrain CF
Eur J Pediatr; 2012 Sep; 171(9):1301-7. PubMed ID: 22113227
[TBL] [Abstract][Full Text] [Related]
8. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome for Down syndrome patients with hematopoietic disorders.
Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
[TBL] [Abstract][Full Text] [Related]
10. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
11. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
[TBL] [Abstract][Full Text] [Related]
12. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
[TBL] [Abstract][Full Text] [Related]
13. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
14. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
Brink DS
Adv Anat Pathol; 2006 Sep; 13(5):256-62. PubMed ID: 16998319
[TBL] [Abstract][Full Text] [Related]
15. Down syndrome and leukemia: insights into leukemogenesis and translational targets.
Mateos MK; Barbaric D; Byatt SA; Sutton R; Marshall GM
Transl Pediatr; 2015 Apr; 4(2):76-92. PubMed ID: 26835364
[TBL] [Abstract][Full Text] [Related]
16. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
[TBL] [Abstract][Full Text] [Related]
17. Unique clinical and biological features of leukemia in Down syndrome children.
Xavier AC; Ge Y; Taub J
Expert Rev Hematol; 2010 Apr; 3(2):175-86. PubMed ID: 21083461
[TBL] [Abstract][Full Text] [Related]
18. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.
Nikolaev SI; Santoni F; Vannier A; Falconnet E; Giarin E; Basso G; Hoischen A; Veltman JA; Groet J; Nizetic D; Antonarakis SE
Blood; 2013 Jul; 122(4):554-61. PubMed ID: 23733339
[TBL] [Abstract][Full Text] [Related]
19. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of myeloid leukaemia in children with Down syndrome in Ireland.
Dowling GP; Piccin A; Gavin KT; Betts DR; Malone A; Cotter M; Sills A; Evans P; O' Marcaigh A; Smith OP
Ir J Med Sci; 2020 Aug; 189(3):979-984. PubMed ID: 32006388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
